Mechanism of butylated hydroxytoluene-associated modification of diethylnitrosamine-induced squamous stomach carcinoma.
The metabolism of butylated hydroxytoluene (BHT) and the effect of BHT on the metabolism of diethylnitrosamine (DEN) was studied in male and female BALB/c mice to further understanding of the selective protection of BHT on the incidence of DEN-induced squamous-stomach carcinomas in female (but not in male) mice. Following intragastric administration of [14C]BHT, the antioxidant was covalently bound to tissue macromolecules. The relative distribution of this bound BHT varied with time; 8 hr after [14C]BHT administration, most of the covalently bound BHT was associated with the protein components; at 96 hr the nucleic acid components bound more BHT than did the protein components. Animals pretreated with BHT and given [14C]DEN intragastrically had lower blood levels of radioactivity and eliminated a larger percentage of DEN and/or its metabolites in the urine and as carbon dioxide than animals given [14C]DEN alone. The binding of DEN and/or its metabolites to cellular macromolecules of the squamous stomach of female animals was decreased following pretreatment with BHT. However, the BHT-associated decrease in DEN binding was also observed in the squamous stomach of male animals and in the liver of both sexes, although the tumour incidence in these target organs for DEN carcinogenesis is not modified by BHT. These results suggest that the BHT-associated decrease in the binding of DEN to DNA is of a generalized rather than a selective nature, and may be insufficient to account for the protective effect of BHT. Two parameters that were found to parallel the susceptibility of DEN target tissues to the anticarcinogenic effects of BHT were the relative degree of inhibition of DEN bound to RNA species and the relative amount of BHT bound to DNA. Thus the anticarcinogenic properties of BHT may be more complex than an induction of enzymes that detoxify the carcinogen and/or an inhibition of enzymes that activate the carcinogen with a resulting decrease in the quantity of carcinogen available for electrophilic reactions.
D000284:Administration, Oral; D000818:Animals; D002084:Butylated Hydroxytoluene / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D002250:Carbon Radioisotopes; D004247:DNA / Q000378:metabolism; D004052:Diethylnitrosamine / Q000378:metabolism* / Q000633:toxicity; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D007441:Intubation, Gastrointestinal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009602:Nitrosamines / Q000378:metabolism*; D011485:Protein Binding; D012737:Sex Factors; D013274:Stomach Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D014018:Tissue Distribution
D002250:Carbon Radioisotopes; D009602:Nitrosamines; D002084:Butylated Hydroxytoluene; D004052:Diethylnitrosamine; D004247:DNA